Imugene
Imugene is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment. Their pipeline includes B-cell immunotherapies and oncolytic virotherapy technologies designed to activate the immune system against cancer cells. Imugene aims to improve the lives of cancer patients by creating more effective and tolerable treatments.
Short position
Imugene (ASX:IMU) has 0.34% of its shares on issue reported as short positions as of 5 Oct 2026, or about 1,858,764 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has fallen 0.30 percentage points. Its highest recorded short interest was 8.10% in August 2023. IMU is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Imugene (IMU) financials
Results, ratios and statements
Latest result
12 months to 30 Jun 2026 (TTM Jun 26) vs TTM Jun 25, figures in AUD, the reporting currency
- Revenue
- n/avs n/a (TTM Jun 25)
- NPAT
- −$105.3Mvs n/a (TTM Jun 25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −$0.32vs −$0.32 (TTM Jun 25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- n/aFY
- EPS YoY
- n/aTTM
Key ratios
Year to 30 Jun 2025 (FY); balance sheet at 30 Jun 2025; prices to 9 Oct 2026
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- n/a
- FCF margin
- n/a
- ROE
- −84.5%
- ROA
- −58.7%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $12.7M
- Net debt / EBITDA
- n/a
- Current ratio
- 1.9×
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | TTM Jun 26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Revenue | n/a | $0M (source: ASX (Markit)) | $0M (source: ASX (Markit)) | $0M (source: ASX (Markit)) | n/a |
| Operating income | −$75.0M | −$86.0M | −$145.7M | −$51.3M | −$50.7M |
| EBITDA | −$100.3M | −$84.8M | −$142.4M | −$51.1M | −$37.6M |
| EBIT | −$105.2M | −$86.0M | −$145.7M | −$51.3M | −$37.8M |
| Interest expense | $90.1K | n/a | n/a | n/a | $106.7K |
| Pretax income | −$105.3M | −$69.0M | −$149.7M | −$39.2M | −$37.9M |
| Tax | $0 | $0 | $0 | $0 | $0 |
| NPAT | −$105.3M | −$69.0M | −$149.7M | −$39.2M | −$37.9M |
| Net interest income | $366.7K | $1.9M | $4.0M | $1.9M | $71.9K |
| EPS basic | −$0.32 | −$0.32 | −$0.72 | −$0.21 | −$0.23 |
| EPS diluted | −$0.32 | −$0.32 | −$0.72 | −$0.21 | −$0.23 |
| Shares | n/a | 219.6M | 215.3M | 188.8M | 172.5M |
- ASX (Markit)
Financial reports
The company's own filings, newest first
- Appendix 4E and Annual ReportAnnual Results28 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results25 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jan 2026via asx_announcements
- March 2025Financial Report31 Dec 2025via crawler
- August 2025Financial Report31 Dec 2025via crawler
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Oct 2025via asx_announcements
- Appendix 4E and Annual ReportAnnual Results26 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Jul 2025via asx_announcements
Showing 10 of 23 reports